Premier Investments vs Myer Holdings shares: which ASX retailer stacks up best?

When everyday investors look for steady returns and income from retail stocks, Premier Investments Ltd (ASX: PMV) and Myer Holdings Ltd (ASX: MYR) are frequent contenders. Both are household names on the ASX with passionate customer followings and large store footprints, but their investment cases have diverged after a major restructuring. If you’re deciding between Premier Investments and Myer shares, here’s how the fundamentals compare right now.

The case for Premier Investments

Premier Investments is a specialist retail group now focused on two leading brands: Peter Alexander, a premium sleepwear and home lifestyle name, and Smiggle, a much-loved children’s stationery retailer famous for its colourful products. After spinning off its apparel chains (like Just Jeans and Jay Jays) to Myer in 2025, Premier now embraces a simpler model that’s less exposed to discount apparel cycles and more to lifestyle and gift-buying. It still retains a large shareholding in Myer.

Highlights of Premier Investments right now:

• Strong dividend yield: Premier is offering an attractive 8.51% dividend yield, all fully franked. Its dividend per share sits at $0.95, a show of confidence in returning capital.
• Solid profitability: With earnings per share of $0.902 and a P/E ratio of 12.38, Premier trades on markedly lower earnings multiples than Myer at present.
• Resilience through refocus: The company has pivoted to two brands with defensible niches (sleepwear and kids’ stationery), and international growth potential continues with Smiggle and Peter Alexander’s expansion into the UK and Asia, according to its company profile.

The case for Myer Holdings

Myer is one of Australia’s largest department store operators, now even bigger following its acquisition of Premier’s former apparel brands (Just Jeans, Jay Jays, Portmans, Dotti, and Jacqui E) in 2025. Alongside its network of around 60 MYER-branded department stores (as of its public company description), Myer now controls a vast stable of retail brands with national reach, targeting value-conscious fashion and home shoppers across the country.

Key considerations for Myer Holdings today:

• High yield for income seekers: Myer’s dividend yield edges out Premier’s at 8.57%, fully franked, with a current dividend per share of $0.02 as per the latest data.
• Wider retail footprint: Myer now operates both large format department stores and hundreds of specialty apparel outlets. This broad network potentially diversifies sales streams and brand risks.
• Turnaround challenge: Myer’s recent financials show strain after integration: it records a negative earnings per share of -$0.178 and carries a higher P/E ratio of 23.70. Note: Myer’s reported P/E ratio may be based on a different earnings measure (e.g. underlying or forward earnings) than the EPS figure shown, which is why they may appear inconsistent.

Valuation comparison

Here’s how key metrics stack up side by side for income, value, and risk:

	Premier Investments	Myer Holdings
Market Cap	$1.91 billion	$337.50 million
P/E Ratio	12.38	23.70
Earnings per Share	$0.902	-$0.178
Dividend Yield	8.51% (100% franked)	8.57% (100% franked)

Premier is the much larger business by market cap and currently trades at a far lower P/E ratio, supported by positive earnings. Myer, despite a slightly higher yield, has negative EPS at the latest read and a notably higher multiple—usually a signal investors expect future profit recovery, but with added risk.

Recent share price performance

Comparing recent momentum using both companies’ closing prices as of 23 September 2026:

• Premier Investments closed at $11.95, up 7.08% on the day, but its year-to-date return sits at -15.8%.
• Myer Holdings closed at $0.18, unchanged for the day, but its year-to-date return is -60.0%.

So while both shares are down for 2026, Myer has dramatically underperformed Premier over the year, with its stock falling much further.

Which is the better buy?

Looking at both the numbers and the business setup, I think Premier Investments makes the stronger case at present. It’s profitable, sports a healthy fully franked yield, and is trading on a much lower P/E ratio than Myer. Its focus on brands with pricing power and some international growth runway adds conviction. By contrast, Myer faces a tough turnaround task post-demerger, with negative earnings and a much weaker share price, despite its large footprint and similar headline yield. If I had to pick a retail stock between these two today, my choice would be Premier Investments.

The post Premier Investments vs Myer: Which ASX Retail Stock is Best? appeared first on The Motley Fool Australia.

More reading

• This ASX 200 share offers 30% upside and a 7% yield
• 5 things to watch on the ASX 200 on Friday
• Here are the top 10 ASX 200 shares today
• Down 64%: Has the market lost interest in Myer shares?
• Why are Premier Investments shares trading higher today?

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Myer and Premier Investments. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial draft. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

It’s been a difficult Friday for Australian investors, but Electro Optic Systems Holdings Ltd (ASX: EOS) shareholders have plenty to smile about.

While the S&P/ASX 200 Index (ASX: XJO) is down 0.54% to 8,655 points, EOS shares are heading in the opposite direction.

The defence tech company’s shares have jumped 7.21% to $11.45, putting it within striking distance of its 52-week high of $12.58.

And with another opportunity opening up in the US defence market, there’s plenty for investors to get excited about.

So, could $15 be the next stop?

EOS unlocks a new US defence opportunity

According to the latest company update, EOS has secured a new procurement pathway for its R400 remote weapon system (RWS).

The system is now listed on the US Joint Interagency Task Force 401 Counter-UAS marketplace.

It allows eligible US government customers to compare counter-drone tech and purchase it through an established US Army contracting arrangement.

Access is also expanding to other allied nations, with 23 countries currently cleared to participate.

The R400 is designed to track and engage ground threats, along with small and medium-sized drones.

While the listing doesn’t represent a new contract, it puts EOS in front of more potential customers and makes the buying process easier.

That’s a pretty good position to be in, particularly as demand for counter-drone tech continues to grow.

I think this could become a valuable sales channel, especially if EOS can turn that additional exposure into more signed contracts.

The numbers are backing it up

It’s not just the growing sales opportunities that have me feeling bullish about EOS.

The company’s latest half-year results showed revenue surged 283% to $168.8 million, compared with $44.1 million a year earlier.

Underlying EBITDA also swung from a $14.9 million loss to a $21.6 million profit.

But what really catches my attention is the company’s order book, which reached a record $846 million at the end of June.

That’s a substantial amount of business already secured, giving EOS plenty of work to deliver over the coming years.

Management is now forecasting full-year revenue of between $360 million and $400 million, including its recently acquired MARSS business.

If achieved, that would represent record annual revenue for the company.

Could EOS shares reach $15?

I think there’s a strong case for further upside, particularly if EOS can turn its growing pipeline into more signed contracts.

And I’m not the only one looking at $15.

According to TipRanks, Canaccord Genuity has a buy rating and $15 price target, while Bell Potter and Ord Minnett have targets of $12.60 and $12.50, respectively.

From $11.45, Canaccord’s $15 target points to potential upside of more than 30%.

Personally, I’d still be comfortable buying EOS shares at these levels with a long-term investment horizon.

The post EOS shares jump 7% as ASX 200 falls. Could $15 be next? appeared first on The Motley Fool Australia.

More reading

• Electro Optic Systems vs Droneshield: Which ASX defence share wins?
• Here are the top 10 ASX 200 shares today
• Could this ASX defence stock rocket back above $13 before Christmas?
• Top 3 ASX defence shares to buy right now
• 4 ASX shares I’d buy with $5,000 in September

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Electro Optic Systems. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

UBS has issued new research reports this week and has identified two companies with market-moving news they think are worth a look.

Let’s see who they like.

Nufarm Ltd (ASX: NUF)

Nufarm shares are up by more than a third over the past 12 months but UBS believes the stock still has a way to run.

The company this week put out new earnings guidance, saying it expected underlying EBITDA to increase by about 25% for the full year.

The company’s seed technologies division was expected to deliver strong growth, led by growth in hybrid seeds and improved omega-3 pricing.

The company’s crop protection division however was expected to have flat earnings.

On the negative side of the ledger Nufarm said it expected to book $90-$110 million in write downs.

UBS said the expected result was a 2%-3% downgrade to previous expectations.

The broker has a price target of $3.50 on Nufarm shares compared to $3.12 currently.

Telix Pharmaceuticals Ltd (ASX: TLX)

UBS has a very bullish price target on Telix after attending an R&D day which the broker said, “showcased the meaningful clinical development for TLX’s diagnostics and therapeutics pipeline across prostate, brain, and kidney cancers”.

The broker said key highlights included progress on prostate cancer therapeutics as well as the company’s Pixclara brain cancer imaging agent.

UBS said:

We believe the event further highlighted TLX’s growing breadth and depth across precision medicine and therapeutics towards being a leading radiopharma business. We see multiple opportunities for meaningful value creation on the horizon, supported by TLX’s deep expertise and clinical development experience with key catalysts over the next 12 months being resubmission/approval for Zircaix, topline data from BiPASS, topline data for TLX597, and data updates from ProstAct Global trial. Furthermore, we believe the recent deal with ITM improves isotope supply chain for ongoing therapeutic portfolio development, creates cost synergy, and adds additional therapeutic pipelines.

Telix just this week announced the $3.3 billion merger deal with ITM, which, Telix said, is the world’s leading supplier of therapeutic radioisotopes and the only producer of globally-scaled, commercial-grade lutetium-77.

Telix said regarding the deal:

The merger will further strengthen Telix’s leadership as a vertically integrated radiopharmaceutical company with the capabilities required to develop, manufacture and deliver innovative treatments to patients globally. The combined organisation will be uniquely positioned as a radiopharmaceutical industry leader, differentiated by a world-class scaled isotope manufacturing business with a validated global distribution network, a market-leading commercial precision medicine platform and the industry’s most extensive therapeutic radiopharmaceutical pipeline.

Telix said ITM grew at a compound annual rate of 40% from 2021 to 2025 and generated US$273 million in revenue in 2025.

UBS has a price target of $22 on Telix shares compared to the current price of $16.01.

The post 2 ASX shares UBS says could increase 13% to 37% appeared first on The Motley Fool Australia.

More reading

• 5 ASX 200 shares upgraded by experts this week
• Buy, hold, sell: New Hope, REA, Telix Pharmaceuticals shares
• What is Bell Potter’s updated view on Nufarm shares after crashing 6%
• 5 things to watch on the ASX 200 on Thursday
• Why is this ASX share crashing 8% on Wednesday?

Motley Fool contributor Cameron England has positions in Telix Pharmaceuticals. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.